Bioxyne (ASX: BXN) is undertaking a review of the results of a clinical study into the efficacy of its lead therapy, HI-164OV, for chronic obstructive pulmonary disease (COPD).
HI-164OV is an orally administered immunotherapeutic that works by controlling bacteria in airways damaged by inhaled toxins.
The company has obtained the individual patient database from the clinical study H-005 and analysis of the full data set is underway.
This will allow Bioxyne to properly compare the information from study H-005 with that of earlier studies.
So far the review has revealed that the earlier H-002/004 study showed benefit in patients of all ages who produced sputum, and that patients under 65 years of age showed benefit in both previous studies (H-002/004 and H-005).
The patent life covering HI-164 is long dated, with the active substance HI-164OV covered to 2029.
Bioxyne now holds data on close to 500 patients with COPD ranging from mild to severe, and in seasons of moderate and low levels of bacterial infection.
Growing target market
COPD is a major target of global pharmaceutical research, with the global incidence growing rapidly in direct proportion to smoking and pollution in the developing world.
The disease is projected to become the third most common cause of death worldwide by 2020, and there are currently no effective treatments.
Annual direct costs to treat COPD are estimated at over $29.5 billion in the U.S., and the estimated annual direct cost to the Australian economy is over $1 billion.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.